Additional clinical-stage programs, including a Phase 2/3 trial in advanced melanoma, underscore momentum across the company’s oncology pipeline Eikon Therapeutics, Inc., a late-stage clinical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback